26 Stomach Cancer 1 1 0 4 4 204 http://clinicaltrials.dfhcc.harvard.edu/trials/204 Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer There is no clear standard of care for metastatic stomach or esophageal cancer in the United States. The purpose of this research study is to determine the differences between two regimens of chemotherapy; Arm A: PCA (Cisplatin, Irinotecan and Bevacizumab) and Arm B: TPCA (Docetaxel, Cisplatin, Irinotecan and Bevacizumab). Docetaxel, Cisplatin, and Irinotecan are traditional chemotherapy drugs. Bevacizumab is an antibody (a protein that attacks a foreign substance in the body). Bevacizumab is believed to stop the formation of new blood vessels that carry nutrients to tumors. Both of the chemotherapy regimens (PCA and TPCA) have been studied in patients with esophageal and gastric cancer, and we are trying to determine if one regimen will keep your cancer from growing and improve how long you can live. Recruiting 26 Stomach Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/26-stomach-cancer 8 Esophageal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/8-esophageal-cancer Phase 2 227 http://clinicaltrials.dfhcc.harvard.edu/trials/227 Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) This is a Phase II, non-randomized, open-label, multi-center study conducted in the USA. The purpose of this trial is to evaluate the use of long term adjuvant imatinib mesylate in patients at significant risk for recurrence following complete resection of primary GIST. Recruiting 26 Stomach Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/26-stomach-cancer Phase 2 1057 http://clinicaltrials.dfhcc.harvard.edu/trials/1057 Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma A pilot study to determine the safety of using perioperative panitumumab with EOX in patients with adenocarcinoma of the esophagus and stomach. Recruiting 26 Stomach Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/26-stomach-cancer 8 Esophageal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/8-esophageal-cancer Phase 1/Phase 2 96 http://clinicaltrials.dfhcc.harvard.edu/trials/96 Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin This research study will examine how often hypersensitivity, or allergic reactions, occur in patients receiving the chemotherapy medication oxaliplatin. Hypersensitivity reactions can vary from a transient skin rash and fever to more severe symptoms such as shortness of breath, chest tightness, and a more severe allergic reaction that can affect blood pressure called anaphylaxis. We will be examining how often hypersensitivity reactions occur and how severe the reactions are when they occur. We will also examine whether there are factors that place people at risk for developing hypersensitivity reactions to oxaliplatin. In an optional portion to this study, we will examine whether allergy skin testing can predict whether someone will develop a hypersensitivity reaction. Participants who develop a moderate to severe allergic reaction to oxaliplatin will be invited to participate in an additional portion of the study examining a desensitization process. This part of the study will examine whether a desensitization process can prevent future hypersensitivity reactions to oxaliplatin in patients who previously developed moderate to severe hypersensitivity reactions and allow therapy with oxaliplatin to continue. Recruiting 19 Pancreatic Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/19-pancreatic-cancer 26 Stomach Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/26-stomach-cancer 8 Esophageal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/8-esophageal-cancer 5 Colorectal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/5-colorectal-cancer 12 Liver Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/12-liver-cancer N/A